Medication adherence and insurance costs

Frame adherence as prevention support

For chronic conditions, medication only delivers intended value when it is taken consistently enough to support the care plan. Insurers can treat adherence as a prevention and support problem, not only as a cost-control metric.

• Focus on helping members stay with appropriate therapy.
• Connect adherence support to chronic-care and prevention programs.
• Avoid claims that a single tool directly reduces costs without measured evidence.

Use Swiss cost context carefully

Swiss medication spending, deductible structures, reimbursement rules, and digital-health reimbursement context matter when discussing adherence economics. These references should frame the problem without implying guaranteed savings.

• Separate system-level cost context from Adherlo-specific outcome claims.
• Make affordability and reimbursement constraints visible.
• Use evidence sources to explain why adherence matters, not to overstate commercial results.

Support before costs rise

Adherence signals can help identify members who may need education, refill support, routine adjustment, or care-team follow-up before the issue becomes more serious.

• Use aggregated patterns to find where support programs are needed.
• Keep individual interventions supportive and transparent.
• Pair digital reminders with human follow-up where risk is higher.

Keep trust and privacy central

Insurance programs should be transparent about data use and focus on support, not punishment. Without trust, even well-designed adherence programs can fail to engage the people they are meant to help.

• Explain what data is collected and why.
• Use consent-based sharing for member-level visibility.
• Avoid incentives or messaging that make patients feel monitored instead of supported.

The strongest payer adherence programs are built around patient trust first.

Measure population patterns responsibly

Population-level adherence trends can help insurers identify where education, device support, or targeted programs may reduce avoidable risk. They should be measured with clear baselines and reviewed against real outcomes over time.

• Define the target population and baseline before launch.
• Track engagement, adherence signals, and follow-up actions separately.
• Review impact with clinical, privacy, and member-experience stakeholders.